ArticleJACS Au2025
AND Logic Gate-Based Dual-Specificity DNA Circuit for Isothermal HBV rcDNA Detection.
Article in JACS Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A toehold-triggered switchable three-way junction protective nanoprobe for RNase H-assisted HBV rcDNA detection.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The quantitative analysis of blood HBV DNA is essential for controlling the spread of HBV and improving the prognosis of individuals infected with the virus. Yet the HBV genome exhibits complex variation, such as multiple-site mutations for entecavir resistance, closely adjacent mutation loci, and the need to distinguish missense from nonsense mutations due to genetic code degeneracy and amino acid mutation conservatism, creating challenges for detection specificity and mutation identification. Herein, this study introduced an AND logic gate-based dual-specificity DNA circuit for HBV DNA detection, integrating toehold-mediated DNA strand displacement and RNase H cleavage through a well-designed probe containing an identification element and an amplification element. By this DNA circuit, we achieved enhanced sensitivity (limit of detection: 29.11 fM) and high specificity to discriminate adjacent single-base mismatches with excellent performance in clinical samples. We envision that this innovative and convenient assay advances point-of-care HBV DNA testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.